Molecular characterization of triple negative breast cancer formaldehyde‐fixed paraffin‐embedded samples by data‐independent acquisition proteomics. Issue 3 (27th October 2021)

• Record Type: Journal Article
• Authors: García‐Adrián, Silvia; Trilla‐Fuertes, Lucía; Gámez‐Pozo, Angelo; Chiva, Cristina; López‐Vacas, Rocío; López‐Camacho, Elena; Zapater‐Moros, Andrea; Lumbreras‐Herrera, María I.; Hardisson, David; Yébenes, Laura; Zamora, Pilar; Sabidó, Eduard; Fresno Vara, Juan Ángel; Espinosa, Enrique
• Is Part Of: Proteomics. Volume 22:Issue 3(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-10-27
• Subjects: molecular characterization -- personalized medicine -- proteomics -- triple negative breast cancer; Proteins -- Separation -- Periodicals; Bioinformatics -- Periodicals; Proteomics -- Periodicals; Genomes -- Periodicals; Molecular genetics -- Periodicals; 572.605
• DOI: 10.1002/pmic.202100110
• Languages: English
• ISSNs: 1615-9853

Abstract

Abstract: Triple negative breast cancer accounts for 15%–20% of all breast carcinomas and is clinically characterized by an aggressive phenotype and poor prognosis. Triple negative tumors do not benefit from targeted therapies, so further characterization is needed to define subgroups with potential therapeutic value. In this work, the proteomes of 125 formalin‐fixed paraffin‐embedded samples from patients diagnosed with non‐metastatic triple negative breast cancer were analyzed using data‐independent acquisition + in a LTQ‐Orbitrap Fusion Lumos mass spectrometer coupled to an EASY‐nLC 1000. 1206 proteins were identified in at least 66% of the samples. Hierarchical clustering, probabilistic graphical models and Significance Analysis of Microarrays were combined to characterize proteomics‐based molecular groups. Two molecular groups were defined with differences in biological processes such as glycolysis, translation and immune response. These two molecular groups showed also several differentially expressed proteins. This clinically homogenous dataset may serve to design new therapeutic strategies in the future.